Search the Newsreel

Amylyx Pharmaceuticals (AMLX) Stock Trades At A Premium After Avexitide Trial Progress

Amylyx Pharmaceuticals (AMLX) stock has seen a 170.4% return over the past year, but its valuation metrics suggest it is trading at a premium. The progress of the avexitide trial, including its completed pivotal trial and potential commercial launch, supports future cash flow expectations, …

Zscaler (ZS) Could Be 5% Undervalued On AI Security Spending Push

Zscaler (ZS) is gaining attention due to increased AI-focused cybersecurity spending plans, Gartner recognition, and positive analyst commentary. While its stock has seen recent volatility, Simply Wall St assesses Zscaler as 4.7% undervalued with a fair value of $192.58, driven by its ability to …

Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands

Madrigal Pharmaceuticals' drug Rezdiffra achieved a $1.3 billion trailing-12-month revenue run rate in Q2 2026, with revenue up 71% year-over-year and over 49,000 active patients. The company is expanding its MASH pipeline to 10 assets, primarily for combination with Rezdiffra, targeting weight loss, liver-fat …

Merit Medical Systems, Inc. $MMSI Shares Purchased by Quantinno Capital Management LP

Quantinno Capital Management LP significantly increased its stake in Merit Medical Systems (MMSI) by 200.3% in the first quarter, now owning 17,612 shares valued at approximately $1.21 million. This comes as institutional investors collectively hold 99.66% of the stock, and analysts maintain a "Moderate …

Milestone’s FDA Win Now Faces A Tougher Test: Sales

Milestone Pharmaceuticals (NASDAQ: MIST) recently gained FDA approval for its lead product, CARDAMYST™ (etripamil) nasal spray, for PSVT. However, the company now faces the challenge of commercializing the product, with early sales and market sentiment being mixed. The success of CARDAMYST depends heavily on …

How Securities Lawsuits Over Trial Disclosures Will Impact Regeneron Pharmaceuticals’ (REGN) Pipeline-Driven Investment Story

Regeneron Pharmaceuticals is facing securities class action lawsuits concerning alleged misleading statements about its Phase III Fianlimab-Libtayo trial. These lawsuits, focusing on disclosure practices regarding trial delays and failure, could influence investor perception of Regeneron's pipeline-driven strategy, especially as the company advances new programs …

Is Eastman Chemical (EMN) A Bargain As KANEBO Expands Use Of Its PET Resin?

Eastman Chemical (EMN) is gaining attention due to KANEBO's expanded use of its Cristal One IM812 specialty PET resin for cosmetic packaging, highlighting Eastman's role in sustainable, advanced materials. Despite recent stock momentum, with a 9.17% 30-day return, its 5-year total shareholder return is …

Empowered Funds LLC Buys 119,202 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

Empowered Funds LLC significantly increased its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 661.6% in the first quarter, adding 119,202 shares to reach a total of 137,220 shares valued at $8.6 million. This move is part of a broader trend of institutional investment, with …

Wall Street Zen Downgrades Westlake Chemical Partners (NYSE:WLKP) to Hold

Wall Street Zen has downgraded Westlake Chemical Partners (NYSE:WLKP) from a "strong buy" to a "hold" rating, while Weiss Ratings simultaneously upgraded it to "buy." Despite the differing opinions, MarketBeat's overall analyst consensus for WLKP remains a "Moderate Buy." The company recently reported quarterly …

Diversified Trust Co. Acquires 4,458 Shares of Air Products and Chemicals, Inc. $APD

Diversified Trust Co. significantly increased its stake in Air Products and Chemicals, Inc. (NYSE:APD) by 230.1% in the second quarter, bringing its total holdings to 6,395 shares valued at approximately $1.88 million. The company reported strong Q2 earnings, beating analyst expectations with an EPS …

IONS Stock Jumps 4% After-Hours — Goldman Sachs Lifts Price Target On Tryngolza Approval

Bank of America Corp DE Boosts Stake in Kiniksa Pharmaceuticals International, plc $KNSA

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Consensus Rating of "Moderate Buy" from Analysts

NRx Pharmaceuticals (NASDAQ:NRXP) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $34.50. Despite this, the company recently missed its quarterly earnings and revenue estimates. Hedge funds and institutional investors hold 4.27% of the stock.

Vertex (VRTX) Stock Looks Above Fair Value On Earnings Yet About Right Overall

Vertex Pharmaceuticals (VRTX) has seen strong multi-year performance, with a 158.2% return over the past five years, but its current valuation suggests it's neither a clear bargain nor obviously overvalued. The stock trades at 29.1x earnings, slightly above Simply Wall St's fair P/E estimate …

ARWR Stock Clocks Best Day In Nearly 8 Months As Analyst Lifts Price Target On Plozasiran Data

Wall Street Zen Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Strong-Buy

Wall Street Zen has upgraded Regeneron Pharmaceuticals (NASDAQ:REGN) from a "buy" to a "strong-buy" rating. This upgrade follows Regeneron's strong quarterly earnings, where it surpassed analyst expectations for both EPS and revenue. Despite positive news regarding pipeline expansion and collaborations, the company faces risks …

Inovio Pharmaceuticals (NASDAQ:INO) Upgraded to "Hold" at Wall Street Zen

Wall Street Zen has upgraded Inovio Pharmaceuticals (NASDAQ:INO) from a "Sell" to a "Hold" rating, though overall analyst opinions remain mixed, with MarketBeat reporting a "Moderate Buy" consensus. The company recently exceeded earnings estimates, reporting a quarterly EPS of negative $0.07 against an expected …

Wall Street Zen Upgrades Vivani Medical (NASDAQ:VANI) to "Hold"

Wall Street Zen has upgraded Vivani Medical (NASDAQ:VANI) from a "sell" to a "hold" rating, contributing to a consensus "Hold" rating with an average price target of $3.75. Analyst opinions are varied, with Lake Street Capital initiating coverage with a "buy" rating and a …

Why Xeris Biopharma Holdings (XERS) Is Up 8.4% After Tightening 2026 Revenue Guidance And Advancing XP-8121

SBC Medical Group (NASDAQ:SBC) Stock Rating Upgraded by Wall Street Zen

Eledon Pharmaceuticals (NASDAQ:ELDN) Upgraded at Wall Street Zen

Wall Street Zen upgraded Eledon Pharmaceuticals (NASDAQ:ELDN) from "strong sell" to "sell," though the broader analyst consensus remains "Hold" with a $9.67 target price. The company reported a quarterly loss of $0.27 per share, missing estimates, and its shares opened at $3.54. Institutional investors …

Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded by Wall Street Zen to Buy Rating

Wall Street Zen has upgraded Oramed Pharmaceuticals (NASDAQ:ORMP) from a "hold" to a "buy" rating, though MarketBeat's overall analyst rating for the company remains "Hold." Oramed Pharmaceuticals opened at $4.48, with a market capitalization of $186.35 million. The company recently reported a quarterly loss …

Wall Street Zen Downgrades Intuitive Surgical (NASDAQ:ISRG) to Hold

Wall Street Zen downgraded Intuitive Surgical (NASDAQ:ISRG) from "Buy" to "Hold," despite a broader "Moderate Buy" consensus among analysts with an average price target of $508.68. Intuitive Surgical recently surpassed quarterly estimates with $2.80 EPS and $2.89 billion in revenue, representing an 18.4% year-over-year …

ICL Group (NYSE:ICL) Upgraded by Wall Street Zen to "Buy" Rating

Wall Street Zen has upgraded ICL Group (NYSE:ICL) from a "hold" to a "buy" rating, despite a broader analyst consensus remaining "Hold" with an average price target of $6.00. This upgrade follows ICL Group's recent quarterly results, which surpassed expectations with an EPS of …

LB Pharmaceuticals (NASDAQ:LBRX) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded LB Pharmaceuticals (NASDAQ:LBRX) from "hold" to "sell" despite a broader analyst consensus of "Moderate Buy" with an average price target of $47.75. The company recently reported a quarterly loss of $1.71 per share, missing consensus estimates, and analysts anticipate a …

NRx Pharmaceuticals (NASDAQ:NRXP) Downgraded to "Sell" Rating by Wall Street Zen

Wall Street Zen has downgraded NRx Pharmaceuticals (NASDAQ:NRXP) from a "hold" to a "sell" rating, despite other analysts maintaining a "Moderate Buy" consensus with an average price target of $34.50. The company's stock opened at $3.27, reflecting a 2.1% drop, and recently reported a …

Verrica Pharmaceuticals (NASDAQ:VRCA) Rating Lowered to Strong Sell at Wall Street Zen

Wall Street Zen downgraded Verrica Pharmaceuticals (NASDAQ:VRCA) from a "sell" to a "strong sell" rating. Despite this, the stock has a consensus "Hold" rating and an average target price of $14.50 from other analysts. The company recently reported a quarterly loss of $0.41 per …

How Investors May Respond To BioCryst (BCRX) Profit Swing, Raised Revenue Outlook And New ESOP Shares

BioCryst Pharmaceuticals reported a significant profit swing in Q2 2026, with revenue of US$218.25 million and net income of US$78.4 million, prompting a raised full-year revenue outlook to US$690 million–US$715 million. Despite this strong quarter, the company still faces a substantial year-to-date net loss …

Kothari Petrochemicals standalone net profit declines 3.19% in the June 2026 quarter

Vishnu Chemicals hosts virtual analyst meet on Aug 19, 2026

Aarey Drugs & Pharmaceuticals standalone net profit declines 25.55% in the June 2026 quarter

(RIGL) Price Dynamics and Execution-Aware Positioning

This article analyzes Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) focusing on its price dynamics and execution-aware positioning based on AI models. It identifies strong near and mid-term sentiment, compelling upside potential due to a lack of resistance levels above the current price, and outlines specific …

Marine Electricals (India) consolidated net profit rises 48.75% in the June 2026 quarter

Primo Chemicals consolidated net profit rises 14.71% in the June 2026 quarter

Bhilwara Technical Textiles consolidated profit up in Q1FY27; standalone down

ACADIA Pharmaceuticals Inc. Stock 12‑Month Price Target Cut to $33.05, Implies 17% Upside

The average 12-month price target for ACADIA Pharmaceuticals Inc. (ACAD) stock has been lowered from $33.65 to $33.05 by 19 analysts, with a range of $17 to $41 per share. This new target suggests a potential 17% upside based on the August 14 closing …